These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 31108015)

  • 1. Efficacy and safety of a two-drug direct-acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6.
    Lawitz E; Gane E; Feld JJ; Buti M; Foster GR; Rabinovitz M; Burnevich E; Katchman H; Tomasiewicz K; Lahser F; Jackson B; Shaughnessy M; Klopfer S; Yeh WW; Robertson MN; Hanna GJ; Barr E; Platt HL;
    J Viral Hepat; 2019 Sep; 26(9):1127-1138. PubMed ID: 31108015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of ruzasvir 60 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4 or 6 infection.
    Lawitz E; Poordad F; Anderson LJ; Vesay M; Kelly MM; Liu H; Gao W; Fernsler D; Asante-Appiah E; Robertson MN; Hanna GJ; Barr E; Butterton J; Kowdley KV; Hassanein T; Sahota A; Gordon SC; Yeh WW
    J Viral Hepat; 2019 Jun; 26(6):675-684. PubMed ID: 30739366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trials.
    Gane EJ; Pianko S; Roberts SK; Thompson AJ; Zeuzem S; Zuckerman E; Ben-Ari Z; Foster GR; Agarwal K; Laursen AL; Gerstoft J; Gao W; Huang HC; Fitzgerald B; Fernsler D; Li JJ; Grandhi A; Liu H; Su FH; Wan S; Zeng Z; Chen HL; Dutko FJ; Nguyen BT; Wahl J; Robertson MN; Barr E; Yeh WW; Plank RM; Butterton JR; Esteban R
    Lancet Gastroenterol Hepatol; 2017 Nov; 2(11):805-813. PubMed ID: 28802816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B): two randomised, phase 2, open-label trials.
    Lawitz E; Buti M; Vierling JM; Almasio PL; Bruno S; Ruane PJ; Hassanein TI; Muellhaupt B; Pearlman B; Jancoriene L; Gao W; Huang HC; Shepherd A; Tannenbaum B; Fernsler D; Li JJ; Grandhi A; Liu H; Su FH; Wan S; Dutko FJ; Nguyen BT; Wahl J; Robertson MN; Barr E; Yeh WW; Plank RM; Butterton JR; Yoshida EM
    Lancet Gastroenterol Hepatol; 2017 Nov; 2(11):814-823. PubMed ID: 28802814
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Asante-Appiah E; Liu R; Curry S; McMonagle P; Agrawal S; Carr D; Rokosz L; Lahser F; Bystol K; Chase R; Black S; Ferrari E; Ingravallo P; Tong L; Yu W; Kozlowski J
    Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30150466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. JNJ-4178 (AL-335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus-Infected Patients Without Cirrhosis: OMEGA-1.
    Zeuzem S; Bourgeois S; Greenbloom S; Buti M; Aghemo A; Lampertico P; Janczewska E; Lim SG; Moreno C; Buggisch P; Tam E; Corbett C; Willems W; Vijgen L; Fevery B; Ouwerkerk-Mahadevan S; Ackaert O; Beumont M; Kalmeijer R; Sinha R; Biermer M;
    Hepatology; 2019 Jun; 69(6):2349-2363. PubMed ID: 30693573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Grazoprevir, ruzasvir, and uprifosbuvir for hepatitis C virus after NS5A treatment failure.
    Wyles D; Wedemeyer H; Ben-Ari Z; Gane EJ; Hansen JB; Jacobson IM; Laursen AL; Luetkemeyer A; Nahass R; Pianko S; Zeuzem S; Jumes P; Huang HC; Butterton J; Robertson M; Wahl J; Barr E; Joeng HK; Martin E; Serfaty L;
    Hepatology; 2017 Dec; 66(6):1794-1804. PubMed ID: 28688129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sofosbuvir-velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals.
    Izumi N; Takehara T; Chayama K; Yatsuhashi H; Takaguchi K; Ide T; Kurosaki M; Ueno Y; Toyoda H; Kakizaki S; Tanaka Y; Kawakami Y; Enomoto H; Ikeda F; Jiang D; De-Oertel S; McNabb BL; Camus G; Stamm LM; Brainard DM; McHutchison JG; Mochida S; Mizokami M
    Hepatol Int; 2018 Jul; 12(4):356-367. PubMed ID: 30030720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of the Combination of Sofosbuvir, Velpatasvir, and the NS3/4A Protease Inhibitor GS-9857 in Treatment-Naïve or Previously Treated Patients With Hepatitis C Virus Genotype 1 or 3 Infections.
    Gane EJ; Schwabe C; Hyland RH; Yang Y; Svarovskaia E; Stamm LM; Brainard DM; McHutchison JG; Stedman CA
    Gastroenterology; 2016 Sep; 151(3):448-456.e1. PubMed ID: 27240903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection: A Randomized Trial.
    Pianko S; Flamm SL; Shiffman ML; Kumar S; Strasser SI; Dore GJ; McNally J; Brainard DM; Han L; Doehle B; Mogalian E; McHutchison JG; Rabinovitz M; Towner WJ; Gane EJ; Stedman CA; Reddy KR; Roberts SK
    Ann Intern Med; 2015 Dec; 163(11):809-17. PubMed ID: 26551263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of sofosbuvir-based direct-acting antiviral regimens for hepatitis C virus genotype 6 in Southwest China: Real-world experience of a retrospective study.
    Wu DB; Jiang W; Wang YH; Chen B; Wang ML; Tao YC; Chen EQ; Tang H
    J Viral Hepat; 2019 Mar; 26(3):316-322. PubMed ID: 30380166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis.
    Esteban R; Pineda JA; Calleja JL; Casado M; Rodríguez M; Turnes J; Morano Amado LE; Morillas RM; Forns X; Pascasio Acevedo JM; Andrade RJ; Rivero A; Carrión JA; Lens S; Riveiro-Barciela M; McNabb B; Zhang G; Camus G; Stamm LM; Brainard DM; Subramanian GM; Buti M
    Gastroenterology; 2018 Oct; 155(4):1120-1127.e4. PubMed ID: 29958855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of current and future regimens for treating genotype 3 hepatitis C virus infection: a large-scale systematic review.
    Fathi H; Clark A; Hill NR; Dusheiko G
    BMC Infect Dis; 2017 Nov; 17(1):722. PubMed ID: 29145802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short article: Faldaprevir, deleobuvir and ribavirin in IL28B non-CC patients with HCV genotype-1a infection included in the SOUND-C3 phase 2b study.
    Zeuzem S; Mantry P; Soriano V; Buynak RJ; Dufour JF; Pockros PJ; Wright D; Angus P; Buti M; Stern JO; Kadus W; Vinisko R; Böcher W; Mensa FJ
    Eur J Gastroenterol Hepatol; 2016 Aug; 28(8):923-6. PubMed ID: 27140229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis.
    Gane E; Poordad F; Wang S; Asatryan A; Kwo PY; Lalezari J; Wyles DL; Hassanein T; Aguilar H; Maliakkal B; Liu R; Lin CW; Ng TI; Kort J; Mensa FJ
    Gastroenterology; 2016 Oct; 151(4):651-659.e1. PubMed ID: 27456384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection.
    Naganuma A; Chayama K; Notsumata K; Gane E; Foster GR; Wyles D; Kwo P; Crown E; Bhagat A; Mensa FJ; Otani T; Larsen L; Burroughs M; Kumada H
    J Gastroenterol; 2019 Aug; 54(8):752-761. PubMed ID: 30868245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection.
    Everson GT; Sims KD; Rodriguez-Torres M; Hézode C; Lawitz E; Bourlière M; Loustaud-Ratti V; Rustgi V; Schwartz H; Tatum H; Marcellin P; Pol S; Thuluvath PJ; Eley T; Wang X; Huang SP; McPhee F; Wind-Rotolo M; Chung E; Pasquinelli C; Grasela DM; Gardiner DF
    Gastroenterology; 2014 Feb; 146(2):420-9. PubMed ID: 24184132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simeprevir plus peginterferon/ribavirin for HCV genotype 1-infected treatment-naïve patients in China and South Korea.
    Wei L; Han T; Yang D; Heo J; Shang J; Cheng J; Chen X; Xie Q; Kim JH; Kalmeijer R; Ouwerkerk-Mahadevan S; Hoeben E; Lenz O; Verbinnen T; Sinha R; Li M; Scott J; Peeters M; Witek J;
    J Gastroenterol Hepatol; 2016 May; 31(5):912-20. PubMed ID: 26777137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Grazoprevir plus peginterferon and ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection: a randomized trial.
    Lagging M; Brown A; Mantry PS; Ramji A; Weilert F; Vierling JM; Howe A; Gendrano IN; Hwang P; Zhang B; Wahl J; Robertson M; Mobashery N
    J Viral Hepat; 2016 Feb; 23(2):80-8. PubMed ID: 26353843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of ledipasvir/sofosbuvir plus ribavirin for 12 weeks in patients with chronic hepatitis C genotype 3 and compensated liver disease.
    Moser S; Kozbial K; Laferl H; Schütz A; Reiberger T; Schwabl P; Gutic E; Schwanke C; Schubert R; Luhn J; Lang T; Schleicher M; Steindl-Munda P; Haltmayer H; Ferenci P; Gschwantler M
    Eur J Gastroenterol Hepatol; 2018 Mar; 30(3):291-295. PubMed ID: 29120906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.